Sophia Genetics, a specialist in data-driven medicine, has raised $13.75m in its series B. The round was led by Invoke Capital, which was joined by Swisscom and Endeavour Vision.
Apart from the cash injection, Sophia gains access to Invoke’s portfolio company Genalys, which uses big data mathematics to analyse genomic information.
Spun out of the Federal Institute of Technology Lausanne in 2011, the Swiss company’s technology makes it possible to diagnose genetic diseases and the DNA of cancer tumours through a combination of next generation sequencing and highly accurate and scalable predictive algorithms. It is hoped that now that Sophia and Genalys have access to each other’s expertise, the technology can be improved even further.
Sophia Genetics previously raised $2.8m in 2013 from undisclosed investors. The company is ahead of its competition in that it is already fully compliant with European data privacy laws. Its technology is currently patent-pending.
Invoke Capital is a $1bn fund launched by founder of Cambridge spin-out Autonomy Mike Lynch, and invests in university spin-outs.
Jurgi Camblong, CEO of Sophia Genetics, said: “Medicine is changing and I am proud of all the work Sophia Genetics is doing to improve diagnosis and treatment of diseases. This new funding will allow us to move faster into European markets. Invoke Capital in particular provides a degree of expertise in data security in cloud and in scalability that will strengthen our genetic sequencing data banking offering immediately.”